FDA clears blood test that flags brain amyloid for Alzheimer’s diagnosis
TL;DR Summary
The FDA has approved Roche’s blood test that detects brain amyloid, a biomarker for Alzheimer’s disease, to help diagnose suspected cases. It is not intended for routine screening and could be easier to administer in primary care than PET scans or cerebrospinal fluid tests, potentially enabling earlier, less invasive confirmation for patients and families.
Topics:business#alzheimers-disease#diagnostic-tests#health#medical-diagnostic-technology#medical-research#us-food-and-drug-administration
- FDA approves a new blood test to detect signs of Alzheimer’s The Washington Post
- Another Alzheimer’s blood test gets OK from FDA CNN
- FDA Approves Alzheimer’s Blood Test Developed by Roche and Eli Lilly WSJ
- Roche, Eli Lilly net FDA approval for first-of-its-kind Alzheimer’s biomarker blood test Fierce Biotech
- FDA approves new blood test for Alzheimer’s disease The Hill
Reading Insights
Total Reads
0
Unique Readers
7
Time Saved
18 min
vs 19 min read
Condensed
99%
3,620 → 54 words
Want the full story? Read the original article
Read on The Washington Post